Odronextamab Demonstrates High Efficacy in Lymphoma Treatments at ASH Meeting

Odronextamab Monotherapy Shows Promise in Follicular Lymphoma Initial results from the safety lead-in portion of the Phase 3 OLYMPIA-1 trial revealed that odronextamab monotherapy led to complete responses in all evaluable patients with previously untreated follicular lymphoma. The trial, which includes a non-randomized safety run-in followed by a randomized efficacy portion, aims to evaluate odronextamab against rituximab plus standard-of-care chemotherapies. Among 13 patients, 12 achieved complete responses by week 12, with no dose-limiting toxicities reported. Common adverse events included cytokine release syndrome, diarrhea, and rash, all manageable with no severe complications.

Durable Responses in Diffuse Large B-Cell Lymphoma Post CAR-T Therapy The primary analysis from an expansion cohort of the ELM-1 trial focused on patients with diffuse large B-cell lymphoma who had progressed after CAR-T therapy. The results, presented in an oral session, underscored the continued efficacy and durability of odronextamab in this challenging patient population.

High Complete Response Rate in Marginal Zone Lymphoma First results from the ELM-2 trial in marginal zone lymphoma demonstrated a high complete response rate among patients with relapsed/refractory disease, further highlighting odronextamab's potential across different B-cell non-Hodgkin lymphoma subtypes.

Expert Commentary Elizabeth Brém, Associate Clinical Professor at UC Irvine, emphasized the paradigm-changing potential of odronextamab in treating previously untreated follicular lymphoma and its remarkable complete response rates in late-line follicular lymphoma. The ongoing Phase 3 OLYMPIA-1 trial's Part 2 will offer the first head-to-head evaluation of odronextamab monotherapy compared to standard-of-care chemo-immunotherapies, eagerly awaited by the medical community.